RecruitingPhase 1NCT07390747

A Trial of SHR-2173 in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single Subcutaneous Administration of SHR-2173 in Healthy Participants

Sponsor

Atridia Pty Ltd.

Enrollment

18 participants

Start Date

Mar 6, 2026

Study Type

INTERVENTIONAL

Conditions

Immunology

Summary

The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of SHR-2173 in healthy participants

Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria5

Healthy white participants.
Ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written informed consent, be able to comply with all the requirements, and able to complete the study.
Male aged between 18 to 45 years of age (inclusive)
Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, body mass index (BMI) between 19.0 and 30.0 kg/m2 (inclusive) at screening.
Men and WOCBP must agree to take highly effective contraceptive methods

Exclusion Criteria7

History or evidence of clinically significant disorders.
Individuals with a history of drug allergies, specific allergies, or known history or suspected of being allergic to the study or same class drug or any component of it.
Receipt of medical devices or another investigational drug within 3 months or 5 half-lives, whichever is longer prior to screening.
The injection site has abnormalities or is deemed by the investigator as unsuitable for subcutaneous injection.
History of excessive smoking in the past 1 month prior to screening
History of illicit or prescription drug abuse or addiction within 1 year of screening, or positive urine drug screen at baseline.
Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.